Al-Dawaa Medical Services Company (4163.SR)
SAR 79.2
(1.02%)
SAR 79.2
(1.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.59 Billion SAR | -0.32% |
| 2022 | 1.64 Billion SAR | 1.47% |
| 2021 | 1.62 Billion SAR | 38.09% |
| 2020 | 1.17 Billion SAR | -4.91% |
| 2019 | 1.23 Billion SAR | 7.63% |
| 2018 | 1.14 Billion SAR | 5.94% |
| 2017 | 1.08 Billion SAR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 433.93 Million SAR | 9.19% |
| 2024 Q2 | 441.67 Million SAR | 1.78% |
| 2023 Q2 | 403.6 Million SAR | -3.91% |
| 2023 Q1 | 420.01 Million SAR | 4.14% |
| 2023 FY | 1.63 Billion SAR | -0.32% |
| 2023 Q4 | 397.39 Million SAR | -5.14% |
| 2023 Q3 | 418.92 Million SAR | 3.8% |
| 2022 Q4 | 403.29 Million SAR | 0.26% |
| 2022 Q3 | 402.25 Million SAR | -3.36% |
| 2022 Q2 | 416.23 Million SAR | -1.71% |
| 2022 Q1 | 423.46 Million SAR | -6.34% |
| 2022 FY | 1.64 Billion SAR | 1.47% |
| 2021 Q3 | 400.57 Million SAR | 2.43% |
| 2021 Q2 | 391.06 Million SAR | 3.56% |
| 2021 Q4 | 452.11 Million SAR | 12.87% |
| 2021 FY | 1.62 Billion SAR | 38.09% |
| 2021 Q1 | 377.6 Million SAR | 29.0% |
| 2020 Q2 | 456.78 Million SAR | 5.87% |
| 2020 FY | 1.17 Billion SAR | -4.91% |
| 2020 Q4 | 292.72 Million SAR | 0.0% |
| 2020 Q3 | 292.72 Million SAR | -35.92% |
| 2020 Q1 | 431.45 Million SAR | 0.0% |
| 2019 FY | 1.23 Billion SAR | 7.63% |
| 2018 FY | 1.14 Billion SAR | 5.94% |
| 2017 FY | 1.08 Billion SAR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 128.79 Million SAR | -1140.729% |
| Nahdi Medical Company | 2.47 Billion SAR | 35.429% |
| Al-Razi Medical Co. | 12.26 Million SAR | -12932.727% |
| Almujtama Alraida Medical Co. | 115.25 Million SAR | -1286.45% |